Source: CureToday articles
The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma.
Recent Content
- Unexpected Support in Tough Times With Multiple Myeloma
- The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma
- Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma
- Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
- Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway
- VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target
- Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
- Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
- Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
- Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study